Company: BNBX
Filing Date: 2025-01-10
Form Type: S-1/A
Source: 0001104659-25-002521
Chunk: 19

Company: BNB PLUS CORP.
Filing Date: 2025-01-10
Form: S-1/A
Chunk 19
---
 at Stony Brook University in Stony Brook, New York, where we have established laboratories
for the manufacture and detection of nucleic acids (DNA and mRNA) to support our various business units. In addition, this location also
houses our NYSDOH CLEP-permitted, CLIA-certified clinical laboratory where we perform MDx Testing Services. The mailing address of our
corporate headquarters is 50 Health Sciences Drive, Stony Brook, New York 11790, and our telephone number is (631) 240-8800.

Implications of Being a Smaller Reporting Company

We are a “smaller reporting company”
as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act, and have elected to take advantage of certain of
the scaled disclosures available to smaller reporting companies. We will continue to be a “smaller reporting company” until
we have $250 million or more in public float (based on our Common Stock) measured as of the last business day of our most recently
completed second fiscal quarter or, in the event we have no public float (based on our Common Stock) or a public float (based on
our Common Stock) that is less than $700 million, annual revenues of $100 million or more during the most recently completed
fiscal year.

We may choose to take advantage of some, but
not all, of these exemptions. We have taken advantage of reduced reporting requirements in this prospectus. Accordingly, the information
contained herein may be different from the information you receive from other public companies in which you hold stock.

<div align='center'>THE OFFERING</div>

| Common              
 Stock offered by us | 41,640,625                                                                                                                 
 shares of Common Stock issuable upon exercise of the Private Placement Warrants (subject to Warrant Stockholder Approval). |

| Use         
 of proceeds | We will not                                                                                                                        
 receive any proceeds from the Common Stock offered by the Selling Stockholders under this prospectus. However, we will receive the 
 proceeds of any cash exercise of the Private Placement Warrants. We intend to use the net proceeds from any cash exercise of the   
 Private Placement Warrants for further development of our Therapeutic DNA Production Services, as well as for working capital and  
 general corporate purposes. See “Use of Proceeds.”                                                                                 |

| Market           
 for Common Stock | Our                                                                                       
 Common Stock is listed on The Nasdaq Capital Market under the symbol “APDN.”              
 On January 8,